GTX-102 ( DrugBank: GTX-102 )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
| 201 | Angelman syndrome | 1 |
65. Primary immunodeficiency
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05531890 (ClinicalTrials.gov) | September 13, 2022 | 31/8/2022 | Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects | Crossover Study to Evaluate the Comparative Bioavailability, Pharmacokinetics, and Safety of GTX-102 Administered as an Oral Spray Compared to Intramuscular Injection and an Oral Solution of Betamethasone in Healthy Subjects | Ataxia Telangiectasia | Drug: GTX-102 medium dose fast Period 1 and Period 2;Drug: GTX-102 medium dose slow Period 1 and Period 2;Drug: GTX-102 high dose fast Period 1 and Period 2;Drug: GTX-102 low dose fast Period 1 and Period 2;Drug: Betamethasone solution as intramuscular injection Period 1 and Period 2;Drug: Betamethasone Oral Solution Period 1 and Period 2 | Acasti Pharma Inc. | NULL | Active, not recruiting | 18 Years | 55 Years | All | 48 | Phase 1 | Canada |
201. Angelman syndrome
Clinical trials : 25 / Drugs : 40 - (DrugBank : 11) / Drug target genes : 22 - Drug target pathways : 20
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04259281 (ClinicalTrials.gov) | February 24, 2020 | 31/1/2020 | A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome | A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS) | Angelman Syndrome | Drug: GTX-102 | Ultragenyx Pharmaceutical Inc | NULL | Recruiting | 4 Years | 17 Years | All | 83 | Phase 1/Phase 2 | United States;Canada;United Kingdom |